The Pfizer Independent Medical Education Grant Request for Proposals: Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology Practice supports eligible organizations in developing independent medical education for healthcare professionals managing patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). This competitive grant program aims to address identified knowledge and competence gaps among community-based clinicians.

Overview

This competitive grant program encourages submissions for independent medical education designed to increase community healthcare professional understanding and competence in the management of patients with R/R LBCL. Projects must focus on the United States. Pfizer supports independent initiatives to improve patient outcomes in areas of unmet medical need aligned with its medical and scientific strategies. The grant requester and grantee are responsible for the design, implementation, and conduct of the independent initiative; Pfizer is not involved in project development or program conduct.

Funding and Benefits

Individual projects requesting up to $250,000 will be considered. The estimated total available budget for this RFP is $500,000. The expected typical grant range is $50,000 to $250,000; smaller, local, or single healthcare institution projects should be at the lower end of this range. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. The maximum project length is 18 months.

Eligibility

Eligible applicants include medical, dental, nursing, allied health, and pharmacy professional schools; healthcare institutions; professional organizations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education or healthcare improvement. Only organizations are eligible to receive grants, not individuals or independent medical practice groups. The applicant must be the project or program lead or an authorized designee. The requesting organization must be legally able to receive award funding directly from Pfizer Inc. For projects offering continuing education credit, the requesting organization must be accredited. Projects must be conducted within the United States.

Research Areas and Activities

Projects will focus on increasing community healthcare professional understanding and competence in the following areas:

• Exploring treatment options for patients with relapsed/refractory LBCL, considering efficacy, safety, and patient-specific factors
• Therapy management strategies to reduce toxicity and optimize outcomes for patients with R/R LBCL
• Mechanisms of drug-resistance and loss of response with emerging treatments

Educational formats that will be considered include professional medical society programs with wide reach to community oncologists, interactive learning, case-based learning, workshops, tumor boards, digital platforms (videos, podcasts, infographics, animations, social media-linked content), on-agenda educational sessions at local or regional live conferences, grand rounds, online articles, newsletter articles, training courses, webinars, and downloadable practice resources. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

The target audience includes hematologists and oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care of people with R/R LBCL in community practice settings.

Application Process

Applications must be submitted via the online portal at www.cybergrants.com/pfizer/knowledge. First-time users should create a password prior to the submission deadline. Applicants must click the "Start A New Knowledge Gap Application" button and complete all required sections of the online application. In the application, select "Yes" for the Competitive Grant question, select the Primary Area of Interest "Oncology – Hematologic - KG", and select the Competitive Grant Program Name "2026 ONC US RR LBCL IME". The project proposal must be uploaded in the General RFP Submission field. Proposals should be single-spaced using Calibri 12-point font and 1-inch margins, with a 15-page limit exclusive of references. The proposal must address goals and objectives, assessment of need, target audience, project design and methods, innovation, evaluation and outcomes, dissemination plan, anticipated project timeline, additional information, organization detail, and budget detail.

Deadline and Timeline

• RFP Release Date: 30 APR 2026
• Submission Deadline: 11 JUN 2026 at 23:59 Eastern Standard Time
• Anticipated Grant Award Notification: 09 JUL 2026
• Anticipated Project Start Date: SEP 2026 or later
• Anticipated Project Duration: No more than 18 months from start date

Applications submitted after the due date will not be reviewed.

Contact Information

For questions regarding this RFP, direct inquiries in writing to the Grant Officer, Sue Lee, at sue.lee@pfizer.com with the subject line "2026 ONC US RR LBCL IME". For technical difficulties with the website, use the "Technical Questions" link at the bottom of the page in CyberGrants. Frequently asked questions regarding the Competitive Grant Program are also available.